Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

Developer of implantable continuous glucose monitoring systems.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Senseonics stock, predicting its price could rise to $2.

Below Average

Financial Health

Senseonics has low sales and profitability, indicating challenges in its financial performance.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring SENS

Wearable Health Stocks: Growth Potential vs Competition

Wearable Health Stocks: Growth Potential vs Competition

Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.

Published: September 12, 2025

Explore Basket
At-Home Treatment Revolution | FDA Approval Impact

At-Home Treatment Revolution | FDA Approval Impact

The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.

Published: September 1, 2025

Explore Basket
Wearable Tech IP Wars: What Investors Should Know

Wearable Tech IP Wars: What Investors Should Know

Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.

Published: August 21, 2025

Explore Basket
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

Published: August 19, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Long‑life CGM thesis

Eversense’s multi‑month implantable sensor targets convenience and adherence advantages versus short‑term sensors, though clinical acceptance and payer reimbursement remain crucial.

🌍

Diabetes market scale

The global diabetes population creates significant demand for monitoring solutions; market growth could support niche players, but larger incumbents intensify competition.

⚑

Regulatory and adoption

Regulatory approvals and distribution partnerships drive uptake, while capital needs and device performance can cause share price volatility.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

TMO

Thermo Fisher Scientific, Inc.

Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.

ISRG

Intuitive Surgical, Inc.

A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties

Frequently asked questions